Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping

Sotatercept And MK-0616 Both Blockbuster-Tipped

Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.

Merck & Co. has achieved trial success for two of its biggest pipeline hopes in cardiovascular medicine, adding weight to its efforts to build a multi-blockbuster presence in the field.

The company achieved better-than-expected Phase III results for its pulmonary arterial hypertension candidate sotatercept and also reported strong Phase IIb data for MK-0616, a potential oral PCSK9

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

13 May 2025

• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

12 May 2025

• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.